Education
About Us
Working with TipRanks
Follow Us
Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
SION Stock Chart & Stats
$31.93
--
Market closed
$31.93
--
Day’s Range― - ―
52-Week Range$7.26 - $34.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)316.73K
Market Cap
$1.41B
Enterprise Value$512.36M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.10
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,139,824
10 Day Avg. Volume353,802
30 Day Avg. Volume316,734
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$39.50Price Target Upside23.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical ExpertiseSION’s clinical development team has previously worked at Vertex Pharmaceuticals, indicating strong expertise in the field.
Drug DevelopmentSION has demonstrated in vitro superiority of its cystic fibrosis (CF) assets vs Vertex's Trikafta using the Cystic Fibrosis Human Bronchial Epithelial (CFHBE) model.
Market PotentialPatients not on Trikafta due to intolerance or poor response are likelier to start on a novel drug, providing a potential market for SION's products.
Bears Say
Clinical PerformanceIf a drug has poor lung bioavailability or patient's baseline disease is too advanced, it could perform less optimally in clinic than predicted by the assay.
Market PenetrationPatients stable on Trikafta are unlikely to be switched to a new drug, limiting the potential market for SION's new products.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $7.25 and its highest was $34.00 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $1.41B.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on May 12, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.448 by -$0.172.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 44,139,824 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.448. Following the earnings report the stock price went up 13.356%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
Sionna Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.50 (23.71% Upside)
$39.50 (23.71% Upside)
Hedge Fund Trend
Increased
By 185.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
257.59%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
SION Stock 12 Month Forecast
Average Price Target
$39.50
▲(23.71% Upside)
Technical Analysis
Stoke Therapeutics
―
Vir Biotechnology
―
Immatics
―
Tango Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
53.96% Insiders
1.74% Mutual Funds
2.21% Other Institutional Investors
40.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---